{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:25:35Z","timestamp":1792268735548,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["26\/31"],"award-info":[{"award-number":["26\/31"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.pupt.2023.102247","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T17:45:46Z","timestamp":1692639946000},"page":"102247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Real world outcomes of CFTR modulator therapy in Australian adults and children"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8691-7597","authenticated-orcid":false,"given":"Stephanie","family":"Kuek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"McCullagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldho","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2023.102247_bib1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2023.102247_bib2","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"J. Pediatr."},{"issue":"12","key":"10.1016\/j.pupt.2023.102247_bib3","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1002\/ppul.25627","article-title":"Review of CFTR modulators 2020","volume":"56","author":"Goetz","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.pupt.2023.102247_bib4","series-title":"The Australian Cystic Fibrosis Data Registry Annual Report 2020","author":"Ahern","year":"2021"},{"issue":"18","key":"10.1016\/j.pupt.2023.102247_bib5","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.pupt.2023.102247_bib6","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"11","key":"10.1016\/j.pupt.2023.102247_bib7","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2023.102247_bib8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.pupt.2023.102247_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"7","key":"10.1016\/j.pupt.2023.102247_bib10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"8","key":"10.1016\/j.pupt.2023.102247_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2213-2600(16)30121-7","article-title":"Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis","volume":"4","author":"Elborn","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2023.102247_bib12","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2023.102247_bib13","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor\u2013ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2023.102247_bib14","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2023.102247_bib15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor- Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.pupt.2023.102247_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for \u226524 Weeks in People With CF and \u22651 F508del Allele: interim Results of an Open-Label Phase Three Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.pupt.2023.102247_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.pupt.2023.102247_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcf.2017.07.001","article-title":"Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2years of treatment with ivacaftor in a real-world setting","volume":"17","author":"Hubert","year":"2018","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.pupt.2023.102247_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1513\/AnnalsATS.201802-149OC","article-title":"Longitudinal trends in real-world outcomes after initiation of ivacaftor. A cohort study from the cystic fibrosis Registry of Ireland","volume":"16","author":"Kirwan","year":"2019","journal-title":"Ann Am Thorac Soc"},{"issue":"9","key":"10.1016\/j.pupt.2023.102247_bib20","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/thoraxjnl-2020-215556","article-title":"Longitudinal effects of ivacaftor and medicine possession ratio in people with the Gly551Asp mutation: a 5-year study","volume":"76","author":"Mitchell","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2023.102247_bib21","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S1569-1993(19)30557-0","article-title":"Real-world Orkambi cohort CorK study (ROCK): a prospective twelve months' analysis addressing the effectiveness of CFTR modulation in patients with cystic fibrosis homozygous for F508del CFTR","volume":"18","author":"Arooj","year":"2019","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.pupt.2023.102247_bib22","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jcf.2019.09.009","article-title":"Longitudinal changes in lung function following initiation of lumacaftor\/ivacaftor combination","author":"Loukou","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.pupt.2023.102247_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1513\/AnnalsATS.202002-144OC","article-title":"Clinical effectiveness of lumacaftor\/ivacaftor in cystic fibrosis patients homozygous for F508del-CFTR","volume":"18","author":"Sagel","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.pupt.2023.102247_bib24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jcf.2020.06.012","article-title":"Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function","volume":"20","author":"Burgel","year":"2021","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.pupt.2023.102247_bib25","first-page":"431","article-title":"Practitioner due diligence: real-world lumacaftor\/ivacaftor use","volume":"25","author":"Stephan","year":"2020","journal-title":"J. Pediatr. Pharmacol. Therapeut."},{"key":"10.1016\/j.pupt.2023.102247_bib26","article-title":"Effects of Lumacaftor-Ivacaftor Therapy on CFTR Function in Phe508del Homozygous Patients with Cystic Fibrosis","volume":"52","author":"Gr\u00e4ber","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2023.102247_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.744705","article-title":"Long-Term outcomes in real life of lumacaftor\u2013ivacaftor treatment in adolescents with cystic fibrosis","volume":"9","author":"Bui","year":"2021","journal-title":"Front. Pediatr."},{"issue":"2","key":"10.1016\/j.pupt.2023.102247_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jcf.2020.06.001","article-title":"Tezacaftor\/ivacaftor in people with cystic fibrosis who stopped lumacaftor\/ivacaftor due to respiratory adverse events","volume":"20","author":"Schwarz","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2023.102247_bib29","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0112-2019","article-title":"Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease","volume":"29","author":"Shteinberg","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.pupt.2023.102247_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209026","article-title":"Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor\/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation","volume":"13","author":"Pohl","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pupt.2023.102247_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Dagenais","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.pupt.2023.102247_bib32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting Elaxacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2023.102247_bib33","series-title":"E-Poster Presented at 14th Australasian Cystic Fibrosis Digital Conference","article-title":"Real world outcomes of CFTR modulator therapy in adults and children","author":"Kuek","year":"2021"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:31:56Z","timestamp":1761082316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553923000597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":33,"alternative-id":["S1094553923000597"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102247","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world outcomes of CFTR modulator therapy in Australian adults and children","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102247"}}